Clinical Trials List
2020-10-01 - 2024-12-31
Phase III
Not yet recruiting3
Terminated4
ICD-10E08.51
Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene
ICD-10E08.52
Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene
ICD-10E08.59
Diabetes mellitus due to underlying condition with other circulatory complications
ICD-10E09.51
Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene
ICD-10E09.52
Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene
ICD-10E09.59
Drug or chemical induced diabetes mellitus with other circulatory complications
ICD-10E11.51
Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene
ICD-10E11.52
Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene
ICD-10E11.59
Type 2 diabetes mellitus with other circulatory complications
ICD-10E13.51
Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene
ICD-10E13.52
Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene
ICD-10E13.59
Other specified diabetes mellitus with other circulatory complications
ICD-9250.70
Diabetes with peripheral circulatory disorders, Type II [non-insulin dependent type][NIDDM type][adult-onset type] or unspecified type ,not stated as uncontrolled
-
Trial Applicant
NOVO NORDISK PHARMA (TAIWAN) LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 杜業豐 Division of Endocrinology
- 林景翰 Division of Endocrinology
- Cheng-Han Lee Division of Cardiovascular Diseases
- Hao-Chang Hung Division of Endocrinology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- LEE-MING CHUANG Division of Endocrinology
- 張恬君 Division of Endocrinology
- 謝易庭 Division of Ophthalmology
- JEN-KUANG LEE Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- 陳怡文 Division of Endocrinology
- 陳俊吉 Division of Cardiovascular Diseases
- Chih-Yiu Tsai Division of Endocrinology
- 黃瓊慧 Division of Endocrinology
- 周星賢 Division of Cardiovascular Diseases
- Jia-Hong Lin Division of Endocrinology
- 洪士淵 Division of Endocrinology
- 林承緯 Division of Endocrinology
- Wen-Cong Lu Division of Endocrinology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
45 participants
-
Global
800 participants
